147249-33-0

Basic information

• Product Name: aspalatone
• Synonyms: aspalatone;Aspalatone Exclusive;JVBIZYPCGNCWIT-UHFFFAOYSA-N
• CAS NO: 147249-33-0
• Molecular Formula: C₁₅H₁₂O₆
• Molecular Weight: 288.254
• Mol File: 147249-33-0.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 466.1°C at 760 mmHg
• Flash Point: 209°C
• Appearance: /
• Density: 1.34g/cm³
• Vapor Pressure: 7.3E-09mmHg at 25°C
• Refractive Index: 1.579
• CAS DataBase Reference: aspalatone(CAS DataBase Reference)
• NIST Chemistry Reference: aspalatone(147249-33-0)
• EPA Substance Registry System: aspalatone(147249-33-0)

Safety Data

• Hazardous Substances Data: 147249-33-0(Hazardous Substances Data)

Usage

General Description

Aspalatone is a synthetic chemical compound that is known for its potential as a bioactive antioxidant. It is commonly used in the cosmetic and skincare industry, where it is believed to help protect the skin from environmental stressors and reduce signs of aging. Aspalatone has also been studied for its potential therapeutic effects in treating neurological disorders, cardiovascular diseases, and inflammatory conditions. Its antioxidant properties are attributed to its ability to scavenge free radicals and reduce oxidative stress in the body, which may contribute to its health-promoting effects. Aspalatone is a promising compound with diverse potential applications in health and wellness.

InChI:InChI=1/C15H12O6/c1-9-14(12(17)7-8-19-9)21-15(18)11-5-3-4-6-13(11)20-10(2)16/h3-8H,1-2H3

Upstream product

• 50-78-2 aspirin 
• 118-71-8 Maltol 
• 5538-51-2 O-acetylsalicyloyl chloride 

Downstream Products

• 69-72-7 salicylic acid 

Relevant articles and documents

Synthesis and antiplatelet effects of the new antithrombotic agent aspalatone with low ulcerogenicity

A new compound, aspalatone (acetylsalicylic acid maltol ester), was synthesized by esterification of acetylsalicylic acid (ASA) and maltol, an antioxidant, and studied for its bleeding time prolongation effect in rats for its antiplatelet aggregation activity in vitro and ex vitro in rats, and for its antithrombotic activity in vivo using the mouse thromboembolism test. Aspalatone treatment (15 mg/kg p.o.) for 10 days prolonged bleeding time by 57% (p 50 of 1.8 x 10-4 mol/l, but, similar to ASA, did not significantly inhibit ADP-induced aggregation. The ability of oral aspalatone to inhibit platelet aggregation in rats ex vivo was compared with other reference antiplatelet drugs. Relative potency was ASA > dipyridamole ? aspalatone > ticlopidine. A single dose of asplatone potently prevented death due to collagen-induced platelet aggregation in mice in vivo with ED50 value of 32 mg/kg p.o., but failed to prevent death due to ADP-induced platelet aggregation. When given for 10 days, aspalatone prevented collagen-induced death by 90% (p 50 values for malondialdehyde degeneration in vitro were 1.1 x 10-4 mol/l and 8.4 x 10-5 mol/l, respectively. These results suggest that aspalatone might be a potential antithrombotic agent with low ulcerogenicity.